New study includes patients aged ≥65 years with atrial fibrillation (AF) at high risk for ischemic stroke or systemic embolism who are deemed ineligible for oral anticoagulant (OAC) treatment due to increased risk of bleedingOCEANIC-AFINA, the latest Phase III study in the OCEANIC clinical trial program, will invest.
The statement said there was no evidence that any of the copied data was being misused. BORN is currently monitoring the internet, including the dark web.